ADP stock price today is slightly higher at $243.32, supported by investor rotation into defensive service-sector names. Technical setups point toward a possible retest of the $245 range within the next week. Pharmaceutical stocks are rallying for a second day on hopes that Pfizer’s deal with the US government, giving it a three-year reprieve from pharmaceutical tariffs, will set a path for other pharmaceutical makers to follow. As a result, Moderna (MRNA) is up more than +8% and AstraZeneca Plc (AZN) is up more than +7% to lead gainers in the Nasdaq 100. Also, Regeneron Pharmaceuticals (REGN) is up more than +7%, and Eli Lilly (LLY) and Biogen (BIIB) are up more than +5%. In addition, Amgen (AMGN), Bristol-Myers Squibb (BMY), Pfizer (PFE), and Merck & Co. (MRK) are up more than +4%. Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 25% over the next couple of years, the future seems bright for Automatic Data Processing. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. At $243.28, ADP stock price today reflects sustained buying interest in a mature dividend-growth stock. The payout ratio remains conservative, allowing reinvestment for long-term expansion while rewarding shareholders.